In non-diabetic patients with depression, phenelzine lowers fasting blood glucose (210), while in various obesogenic mouse models, it reduces hepatic MDA, improves insulin sensitivity, increases plasma insulin, maintains normoglycemia, and decreases inflammation (211, 212). Here, INS is linked to depressive disorder.